Navigation Links
Elekta Announces Clinical Start-up of Elekta Synergy(R) S at UPMC
Date:1/10/2008

PITTSBURGH and ATLANTA, Jan. 10 /PRNewswire/ -- Treatments have commenced on the new Elekta Synergy(R) S at University of Pittsburgh Medical Center (UPMC). UPMC is a world-leading provider of intra- and extracranial stereotactic radiosurgery.

The clinical start of treatments began October 30, 2007 with a colon cancer treatment followed by a lung patient. Since then, the vast majority of patients treated with Elekta Synergy S are spine stereotactic radiosurgery (SRS) patients, most of which are treated in a single session.

Elekta Synergy S is a state-of-the-art digital linear accelerator with ultra-precise patient alignment that uses Elekta's advanced X-ray Volume Imaging (XVI) to acquire ultra low dose 3D cone beam CT volumetric images with the patient in the treatment position for accurate patient alignment. The system then delivers higher, more conformal doses of radiation to the target due to the unique MLC design of Elekta Synergy S, called Beam Modulator(TM). The Beam Modulator was designed for single session SRS, which results in fewer clinic visits for the patient, as well as faster, more efficient treatment times.

"Elekta Synergy S is a very good, very reliable machine," says M. Saiful Huq, Ph.D., FAAPM, FinstP, professor and director of Medical Physics, Department of Radiation Oncology at UPMC Cancer Centers. "With the Elekta Volume View(TM) cone beam CT, we can localize treatment directly to the tumor and spare surrounding healthy tissue. And the robotic HexaPOD(TM) tabletop allows six degrees of correction in rotational or translational errors for extreme accuracy."

With these capabilities, Elekta Synergy S provides a powerful combination of software-driven, image-guided accuracy and highly conformal beam shaping - two critical requirements for maximizing precision and improving patient outcomes in stereotactic treatment.

UPMC partners with Elekta to develop new technologies

UPMC and Elekta have worked toge
'/>"/>

SOURCE Elekta, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
2. Elekta Demonstrates Commitment to Stereotactic Innovation at EANS
3. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
4. Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions
5. Elekta Launches New Linear Accelerator at 2007 ESTRO to Expand Cancer Treatment Availability
6. Elekta Brings Intelligent Ways to Manage Motion During Cancer Treatment to ESTRO
7. Elekta Displays Complete Volumetric Intensity Modulated Arc Therapy Solutions at ESTRO
8. Elekta Announces New Cancer Care Solutions and Highlights Personalized Efficiency at ASTRO 2007
9. Elekta Announces Elekta Infinity - a New System for Faster and More Precise Treatment of Cancer Tumors
10. Beaumont Hospital, Royal Oak Treats Its First Patients With Elekta Axesse
11. Elekta Showcases Stereotactic Systems for Cancer Care at Astro 2007

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)...NCISCO, Dec. 3 VIA Pharm... company focused on the development of compounds f...isease, today announced that it has completed the ... trial of VIA-2291. ,, The FDG-PET trial enrol...in the US and Canada including Massachusetts Gener...
(Date:12/3/2009)...LPHIA, Dec. 3 Shire plc ...biopharmaceutical company, today announced a volun...drawal of one lot of the Attention-Deficit/Hyperac...re is taking this action because some Daytrana pat...ir release liner removal specification, and as a r...
(Date:12/3/2009)...IN, Calif., Dec. 3 Pereg...announced that it will release its financial resul...ecember 10, 2009 at 7:00 a.m. EST and will host a ... at 11:30 a.m. EST on the same day. ,, Peregrin...ts for the second quarter ended October 31, 2009 a...
(Date:12/3/2009)..., Mass., Dec. 3 Invernes...al leader in enabling individuals to take charge o... diagnostics and health management, has declared a...rtible Perpetual Preferred Stock ( IMA-PB). The di... an amount per share equal to the quotient of (a) ...
Breaking Biology Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2
...ovember 28, Evotec AG (Frankfurt Stock Exchange: E...laus Maleck have been appointed to,the Company,s M...icer and,Chief Financial Officer., Jorn Aldag, Pr...id:,"I,m extremely pleased to announce the additio...anagement Board. Both are individuals with a wealt...
...asdaq:,PPDI) today announced the appointment of Jo... clinical operations, to lead the company,s delive... America and the Caribbean.,Based in Mexico City, ...PPD,clinical services in the region., "Dr. Viramo...tical,industry in Mexico, extensive clinical resea...
...ceutical Company Inc. (Nasdaq: NSTK ) announced t...ts Focus on Healthcare Conference on,Wednesday, De...llennium,Broadway Hotel in New York City., To acc...ease log on to,Nastech,s website at http://www.na...resentation in order to register and download any ...
Other Biology Technology:Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board 2Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board 3Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board 4Viramontes to Lead PPD Clinical Operations in Mexico, Central America and the Caribbean 2Viramontes to Lead PPD Clinical Operations in Mexico, Central America and the Caribbean 3
(Date:12/3/2009)...el Research Institute (VARI) researchers have dete...id (ABA) works at the molecular level to help plan...ht and cold. Their findings, published in the jou...ve in harsh environments around the world and comb... have implications for stress disorders in humans....
(Date:12/3/2009)...nge in warmer water, according to an intriguing ne...me species more aggressive. , Experiments with t...t Barrier Reef have shown for the first time that ...onsistently bold, and that these individual differ...ise. , A slight lift of just one or two degrees ...
(Date:12/3/2009)...nubbing? Your genetics, not your friends, may be a...-like painkillers, called opioids, relieve not onl...stress. Now, a new study reviewed by Faculty of 10...enetic differences in the gene for the opioid rece...nses to social rejection. , In the study publis...
Breaking Biology News(10 mins):VAI researchers find long awaited key to creating drought resistant crops 2VAI researchers find long awaited key to creating drought resistant crops 3Fish with attitude: Some like it hot 2eCardio Named One of Houstons Fastest Growing Technology Companies at the 2009 Houston Business Journal FastTech 50 Awards Luncheon 6165 1eCardio Named One of Houstons Fastest Growing Technology Companies at the 2009 Houston Business Journal FastTech 50 Awards Luncheon 6165 2eCardio Named One of Houstons Fastest Growing Technology Companies at the 2009 Houston Business Journal FastTech 50 Awards Luncheon 6165 3Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17 2009 6162 1Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17 2009 6162 2Executives Reveal Secrets to Capitalize on New Developments in Pharmaceutical Marketing Research 6159 1Executives Reveal Secrets to Capitalize on New Developments in Pharmaceutical Marketing Research 6159 2
...p a clearer picture of what makes some people stan...earchers who last year identified the first common...tified a further twenty regions of the genome whic...cm. , The results, published together with two i...ure Genetics, mean that scientists now know of doz...
...s that desperately try to reach for a break in the...e same affliction: Shade avoidance syndrome or SAS...ght to light by researchers at the Salk Institute ...eighbors shade, plants switch on a natural chemica...rmone auxin that lets a plant grow and ultimately ...
...ute for Medical Research (Burnham) may have found ... showing the link between a certain protein and th...feed breast tumors. Like mortar between bricks in ...tick together and collectively form tissues. Cance...op producing T-cadherin, and in tumors, only the b...
Other Biology News:A tall story: New research adds to growing body of knowledge of genetics of height 2A place in the sun 2A place in the sun 3T-cadherin affects blood vessel growth in breast cancer, hormone from fat cells may play a role 2T-cadherin affects blood vessel growth in breast cancer, hormone from fat cells may play a role 3
...ti-purpose, high gel-strength agarose suitable for...m conventional constant field to Pulsed Field Gel ...th and exclusion limits, Multi ABgarose can effect...nning times. This in turn means reduced band diffu...
...is a molecular screening, low melting point agaros...g. It is recommended for separation of nucleic aci...icro ABgarose is also suited to capillary electrop...ques. At a 3% concentration, Micro ABgarose gels a...
Sheep Anti-Salmonella Shoreditch Polyclonal Antibody, Unconjugated from Abcam
Mouse Anti-Drosophila Melanogaster Achaete protein Monoclonal Antibody, Unconjugated from Developmental Studies Hybridoma Bank
Biology Products: